Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases

Annals of Surgical Oncology

Volumn 20, Issue 5, 2013, Pages 1462-1469

  Van Den Broek, Maartje A J ^a   Vreuls, Celien P H ^a   Winstanley, Ali ^b   Jansen, Rob L H ^a   Van Bijnen, Annemarie A ^a   Dello, Simon A W G ^a   Bemelmans, Marc H ^a   Dejong, Cornelis H C ^a   Driessen, Ann ^a   Olde Damink, Steven W M ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; HYALURONIC ACID; OXALIPLATIN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL LIVER METASTASIS; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER VEIN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PARTIAL HEPATECTOMY; PORTAL VEIN; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; RADIAL ARTERY; SENSITIVITY AND SPECIFICITY; SPLANCHNIC BLOOD FLOW; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HEPATECTOMY; HEPATIC VEINS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; HYALURONIC ACID; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PORTAL VEIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIAL ARTERY; SEVERITY OF ILLNESS INDEX;

EID: 84880071960     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2915-8     Document Type: Article

References (44)

1. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-16.
2. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1271-80.
3. Lam VW, Spiro C, Laurence JM, et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2011;19:1292-301.
4. DeLeve LD. Hepatic microvasculature in liver injury. Semin Liver Dis. 2007;27:390-400.
5. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin- associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430-9.
6. Soubrane O, Brouquet A, Zalinski S, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251:454-60.
7. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983-90.
8. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1-7.
9. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-72.
10. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118-24.
11. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2010;18:421-30.
12. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729-64.
13. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
14. Jones OM, Rees M, John TG, Bygrave S, Plant G. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg. 2005;92:1165-8.
15. Narita M, Oussoultzoglou E, Fuchshuber P, et al. What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy? Ann Surg Oncol. 2012;19:2526-38.
16. Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28:2549-55.
17. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29:1779-91.
18. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997;242:27-33.
19. Lindqvist U. Is serum hyaluronan a helpful tool in the management of patients with liver diseases? J Intern Med. 1997;242:67-71.
20. Fried MW, Duncan A, Soroka S, et al. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 2001;27:635-9.
21. Eriksson S, Fraser JR, Laurent TC, Pertoft H, Smedsrod B. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res. 1983;144:223-8.
22. Elvevold K, Smedsrod B, Martinez I. The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity. Am J Physiol Gastrointest Liver Physiol. 2008;294:G391-400.
23. Bronsther OL, Rao PN, Pinna A, et al. Effluent levels of hyaluronic acid can predict ultimate graft outcome after clinical liver transplantation: a prospective series. Transplant Proc. 1993;25:1538-40.
24. Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009;10:278-86.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
26. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26.
27. van Dam RM, Hendry PO, Coolsen MM, et al. Initial experience with a multimodal enhanced recovery programme in patients undergoing liver resection. Br J Surg. 2008;95:969-75.
28. van den Broek MA, van Dam RM, van Breukelen GJ, et al. Development of a composite endpoint for randomized controlled trials in liver surgery. Br J Surg. 2011;98:1138-45.
29. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13.
30. van den Broek MA, Bloemen JG, Dello SA, van de Poll MC, Olde Damink SW, Dejong CH. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol. 2011;55:337-45.
31. van de Poll MC, Siroen MP, van Leeuwen PA, et al. Interorgan amino acid exchange in humans: consequences for arginine and citrulline metabolism. Am J Clin Nutr. 2007;85:167-72.
32. de Jong MC, van Dam RM, Maas M, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford). 2011;13:745-52.
33. Mehta NN, Ravikumar R, Coldham CA, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:782-6.
34. Gibson PR, Fraser JR, Colman JC, Jones PA, Jennings G, Dudley FJ. Change in serum hyaluronan: a simple index of short-term drug-induced changes in hepatic sinusoidal perfusion. Gastroenterology. 1993;105:470-4.
35. Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol. 1991;12:94-9.
36. Alston-Smith J, Pertoft H, Laurent TC. Hyaluronan synthesis by rat liver stellate cells is enhanced under endotoxic conditions. Matrix. 1993;13:313-22.
37. Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 2008;48:920-30.
38. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-6.
39. 11C]Hyaluronan uptake with positron emission tomography in liver disease. Eur J Clin Invest. 2000;30:600-7.
40. Lindqvist U, Groth T, Loof L, Hellsing K. A hyaluronan-loading test applied to patients with liver and joint diseases. Clin Chim Acta. 1992;210:119-32.
41. Rubbia-Brandt L, Tauzin S, Brezault C, et al. Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther. 2011;10:687-96.
42. Agostini J, Benoist S, Seman M, et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol. 2012;56:869-76.
43. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006;368:33-47.
44. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12:351-5.